These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 35445737)

  • 1. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).
    Khabibov M; Garifullin A; Boumber Y; Khaddour K; Fernandez M; Khamitov F; Khalikova L; Kuznetsova N; Kit O; Kharin L
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35445737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
    Verdugo E; Puerto I; Medina MÁ
    Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT/GSK3β Signaling in Glioblastoma.
    Majewska E; Szeliga M
    Neurochem Res; 2017 Mar; 42(3):918-924. PubMed ID: 27568206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.
    da Silva ALL; de Araújo TPG; de Albuquerque Ferreira SC; Leite AB; da Silva JKS; Albuquerque LWN; de Lima ARV; Barros HCS; Silva LR; da Silva-Júnior EF; de Araújo-Júnior JX; Neto VM; de Queiroz AC; Alexandre-Moreira MS
    Curr Protein Pept Sci; 2024; 25(1):12-26. PubMed ID: 37653631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.
    Sami A; Karsy M
    Tumour Biol; 2013 Aug; 34(4):1991-2002. PubMed ID: 23625692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
    Aguila B; Morris AB; Spina R; Bar E; Schraner J; Vinkler R; Sohn JW; Welford SM
    Cancer Lett; 2019 Oct; 462():33-42. PubMed ID: 31377205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.
    Barzegar Behrooz A; Talaie Z; Jusheghani F; Łos MJ; Klonisch T; Ghavami S
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells.
    Udawant S; Litif C; Lopez A; Gunn B; Schuenzel E; Keniry M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.
    Tuncel G; Kalkan R
    Med Oncol; 2018 Aug; 35(9):122. PubMed ID: 30078108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
    Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
    Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-548x and miR-4698 controlled cell proliferation by affecting the PI3K/AKT signaling pathway in Glioblastoma cell lines.
    Kalhori MR; Arefian E; Fallah Atanaki F; Kavousi K; Soleimani M
    Sci Rep; 2020 Jan; 10(1):1558. PubMed ID: 32005873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circular RNAs and glioblastoma multiforme: focus on molecular mechanisms.
    Salami R; Salami M; Mafi A; Vakili O; Asemi Z
    Cell Commun Signal; 2022 Jan; 20(1):13. PubMed ID: 35090496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the AKT pathway in glioblastoma.
    McDowell KA; Riggins GJ; Gallia GL
    Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
    Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
    Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma.
    Wang G; Wang JJ; Tang HM; To SS
    Arch Biochem Biophys; 2015 Aug; 580():64-74. PubMed ID: 26142886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers.
    Lan Z; Li X; Zhang X
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.